GlaxoSmithKline PLC — Board/Management Information 2021

May 6, 2021

National Storage Mechanism | Additional information

RNS Number : 8440X

GlaxoSmithKline PLC

06 May 2021

GlaxoSmithKline plc

GSK announces changes to its Board and Committees

GlaxoSmithKline plc today announces the following changes to its Board and Committee membership effective 6 May 2021.

As previously announced, Dr Anne Beal has joined the Board as an Independent Non-Executive Director. She has been appointed a member of the Corporate Responsibility Committee.

In addition, Charles Bancroft has been appointed a member of the Nominations & Corporate Governance and Science Committees. These appointments are in addition to his role as Chairman of the Audit & Risk Committee and membership of the Transformation & Separation Committee. 

Note

1.	From 6 May 2021 the Board of GSK comprises
	Sir Jonathan Symonds  Emma Walmsley                       Iain Mackay                               Dr Hal Barron                Vindi Banga                  Charles Bancroft Dr Anne Beal Dr Vivienne Cox                        Lynn Elsenhans             Dr Jesse Goodman                   Dr Laurie Glimcher                     Urs Rohner	Non-Executive Chairman Chief Executive Officer Chief Financial Officer Chief Scientific Officer and President, R&D Senior Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director Independent Non-Executive Director

V A Whyte

Company Secretary

6 May 2021

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

BOABLGDUCSGDGBL